Read by QxMD icon Read

Leukemia & Lymphoma

Mads Emil Bjørn, Marie Klinge Brimnes, Sif Gudbrandsdottir, Christen Lykkegaard Andersen, Henrik Enghusen Poulsen, Trine Henriksen, Hans Carl Hasselbalch, Claus Henrik Nielsen
The role of excess reactive oxygen species (ROS) with consequent DNA/RNA damage is now recognized as a hallmark of cancer. In JAK2V617F mutated myeloproliferative neoplasms, ROS have been suggested to be important factors in disease initiation and progression. Ruxolitinib is the most widely used drug for myelofibrosis, because it improves symptom-score. However, both the anti-clonal potential and improvement in overall survival are limited. We investigated the impact of ruxolitinib on formation of superoxide radical and hydrogen peroxide by monocytes in sequentially acquired blood samples from patients with myelofibrosis...
February 20, 2019: Leukemia & Lymphoma
Noemi Horvath, Andrew Spencer, Melita Kenealy, Douglas Joshua, Philip J Campbell, Je-Jung Lee, Jian Hou, Lugui Qiu, Anna Kalff, Tiffany Khong, Anil Londhe, Sarah Siggins, Maximiliano van Kooten Losio, Michael Eisbacher, H Miles Prince
Efficacy and safety of bortezomib-based consolidation following ASCT were investigated in newly diagnosed multiple myeloma patients from Australia, Korea, and China. Patients received three cycles of bortezomib-cyclophosphamide-dexamethasone induction followed by high-dose therapy/ASCT, then were randomized (1:1) to consolidation with TP (thalidomide 100 mg/d for ≤12 months/until disease progression; prednisolone 50 mg on alternate days indefinitely/until disease progression; n = 100) or VTP (subcutaneous bortezomib 1...
February 19, 2019: Leukemia & Lymphoma
Takaaki Konuma, Seiko Kato, Maki Oiwa-Monna, Mai Mizusawa, Masamichi Isobe, Kazuaki Yokoyama, Satoshi Takahashi, Arinobu Tojo
No abstract text is available yet for this article.
February 18, 2019: Leukemia & Lymphoma
Marie-Claude Pelland-Marcotte, Jeremiah Hwee, Jason D Pole, Paul C Nathan, Lillian Sung
Infections are a common complication of treatment for pediatric acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). Less is known about infections occurring after treatment. We performed a systematic review of the literature to assess the incidence of infections after therapy completion in children and young adults with ALL or AML. Twenty-eight studies, with 4138 patients, were included. Four studies reported infections in patients who did not undergo hematopoietic stem cell transplant (HSCT)...
February 18, 2019: Leukemia & Lymphoma
Seung-Ho Shin, Yeon Jeong Kim, Danbi Lee, Duck Cho, Young Hyeh Ko, Junhun Cho, Woong-Yang Park, Donghyun Park, Seok Jin Kim, Won Seog Kim
Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We designed a panel targeting 66 genes associated with NHLs and performed targeted deep sequencing to analyze plasma cfDNA from patients with various subtypes of NHLs. Genetic profiling in plasma cfDNA using the method resulted in 88...
February 18, 2019: Leukemia & Lymphoma
Mahesh Swaminathan, Gautam Borthakur, Tapan M Kadia, Alessandra Ferrajoli, Yesid Alvarado, Naveen Pemmaraju, Kristy Bodden, Brittany Yearby, Marina Konopleva, Joseph Khoury, Carlos Bueso-Ramos, Guillermo Garcia-Manero, Courtney D DiNardo
Hypomethylating agents (HMA) are the standard of care for treatment of myelodysplastic syndromes (MDS). HMA-failure MDS has extremely poor prognosis. This study was designed to explore the utility of eltrombopag in post-HMA failure MDS patients. Patients were treated in one of two arms: eltrombopag as monotherapy (Arm A), or with continuation of HMA (Arm B). The starting eltrombopag dose was 200 mg orally daily. Twenty-nine patients with a median age of 72 years (42-84) were enrolled. The median number of prior treatment was 1 (1-5)...
February 18, 2019: Leukemia & Lymphoma
Marie Jarošová, Karla Plevová, Jana Kotašková, Michael Doubek, Šárka Pospíšilová
Cytogenetic examination and the detection of chromosomal aberrations in chronic lymphocytic leukemia (CLL) is an integral part of prognostic stratification and treatment decisions. Improvements in cytogenetic methods, notably the introduction of the cell stimulation method, have led to the detection of chromosomal aberrations in 80% of CLL cases. A comprehensive analysis of cytogenetic aberrations recently showed that complex karyotypes (CKs) defined as the detection of either three or more or five or more chromosomal changes in a karyotype have a poor prognostic impact...
February 18, 2019: Leukemia & Lymphoma
Tzung-Huei Lai, Shaneice Mitchell, Pei-Jung Wu, Shelley Orwick, Chaomei Liu, Janani Ravikrishnan, Jennifer Woyach, Alice Mims, William Plunkett, Vinay K Puduvalli, John C Byrd, Rosa Lapalombella, Deepa Sampath
No abstract text is available yet for this article.
February 18, 2019: Leukemia & Lymphoma
Louis Perol, Eric Grignano, Adrien Contejean, Lauris Gastaud, Marielle Legoff, Patricia Franchi, Bénédicte Deau-Fischer, Lise Willems, Didier Bouscary, Jerome Tamburini
No abstract text is available yet for this article.
February 18, 2019: Leukemia & Lymphoma
Dao-Xing Deng, Hong-Hu Zhu, Yan-Rong Liu, Ying-Jun Chang, Guo-Rui Ruan, Jin-Song Jia, Hao Jiang, Qian Jiang, Xiao-Su Zhao, Xiao-Jun Huang
Acute myeloid leukemia (AML) patients with biallelic CEBPA (bi CEBPA) mutations are considered prognostically favorable, but 38-58% of them still relapse. Therefore, recognizing patients with a high risk of relapse is important. We retrospectively analyzed 83 bi CEBPA AML. Minimal residual disease (MRD) was detected by multiparameter flow cytometry (MFC). Patients with MRD positivity during consolidation chemotherapy had inferior 3-year CIR (55% vs. 36.7%; p = .037) and RFS (45% vs. 63.3%; p = .037) than those with MRD negativity...
February 18, 2019: Leukemia & Lymphoma
Anureet C Copeland, Matthew C Foster, Benyam Muluneh, James G Xenakis, Anastasia Ivanova, Olga Frankfurt, Monique Clayton, Anderson Black, Barbara Rapchak, Robert S Wehbie
No abstract text is available yet for this article.
February 18, 2019: Leukemia & Lymphoma
Deepesh Lad, Qing Huang, Romy Hoeppli, Rosa Garcia, Lixin Xu, Megan Levings, Kevin Song, Raewyn Broady
The role of regulatory T-cells (Treg) and Th17 cells in the progression of multiple myeloma has been unclear. There are conflicting reports of the Treg and Th17 frequency being increased, decreased, and unchanged as compared with controls. In this study, we sought to characterize the T-cell subsets including Treg function in both blood and marrow compartments of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). The Treg/Th17 ratio is skewed toward the suppressive phenotype in MGUS and MM...
February 18, 2019: Leukemia & Lymphoma
Liat Shargian-Alon, Dafna Yahav, Uri Rozovski, Sara Dovrat, Irina Amitai, Michal Sela-Navon, Oren Pasvolsky, Pia Raanani, Moshe Yeshurun
Data regarding presentation and management of human herpes virus 6 (HHV-6) reactivation among autologous hematopoietic cell transplantation (HCT) recipients are limited. We retrospectively reviewed medical charts of all autologous HCT patients tested for HHV-6 reactivation due to suspected clinical presentation between 1/2012 and 8/2017. Among 328 autologous HCT recipients, 44 patients were tested for HHV-6 reactivation. Thirty patients tested positive; 29 (97%) had sustained fever, six (20%) had rash and four (13%) had pneumonia...
February 18, 2019: Leukemia & Lymphoma
Elizabeth H Phillips, Stephen Devereux, John Radford, Naheed Mir, Toyin Adedayo, Laura Clifton-Hadley, Rod Johnson
No abstract text is available yet for this article.
February 18, 2019: Leukemia & Lymphoma
Filiz Yucebay, Christina Matthews, Marcin Puto, Junan Li, Basem William, Samantha M Jaglowski, Sam L Penza, Sumithira Vasu, Don M Benson, Leslie A Andritsos, Steven M Devine, Yvonne A Efebera, Julianna V F Roddy
Acute graft-versus-host-disease (aGVHD) is a complication after allogeneic stem cell transplant. After the failure of treatment with high dose corticosteroids, steroid-refractory aGVHD (SR aGVHD) is associated with high rates of mortality. Tocilizumab has evidence of activity in SR aGVHD. For patients ineligible for trials, the OSU James Comprehensive Cancer Center has been utilizing tocilizumab as first-line therapy for SR aGVHD. We retrospectively report on 15 patients who received tocilizumab. aGVHD grading and responses were based on consensus criteria...
February 15, 2019: Leukemia & Lymphoma
Joshua B Dault, Alexander N Slade, Sherry Zhao, Shiyu Song
No abstract text is available yet for this article.
February 14, 2019: Leukemia & Lymphoma
Koen Van Besien, Lizamarie Bachier-Rodriguez, Michael Satlin, Maxwell A Brown, Usama Gergis, Danielle Guarneri, Jingmei Hsu, Adrienne A Phillips, Sebastian A Mayer, Amrita D Singh, Rosemary Soave, Adriana Rossi, Catherine B Small, Thomas J Walsh, Hanna Rennert, Tsiporah B Shore
Epstein-Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD) are common and potentially fatal complications after allogeneic transplantation with mismatched donors and T-cell depletion. Haplo-cord transplantation combines a mismatched UCB graft with third-party cells. Conditioning involves thymoglobulin. EBV reactivation and PTLD were common in initial patients. As of March 2017, we administered a prophylactic dose of rituximab 375 mg/m2 pre-transplant. Among 147 patients who did not receive rituximab, the cumulative incidence of post-transplant EBV reactivation and of EBV PTLD was 13% and 8%, respectively...
February 10, 2019: Leukemia & Lymphoma
Peter Martin
No abstract text is available yet for this article.
February 8, 2019: Leukemia & Lymphoma
Kanchun Dai, Qianying Zhang, Yingying Li, Luyi Wu, Shenghui Zhang, Kang Yu
To assess plasma fibrinogen levels as a biomarker to predict the prognosis and treatment outcome in acute myeloid leukemia (AML), a retrospective study of 215 patients with AML excluding M3 was conducted in a single center. Patients were divided into low and high group according to the cutoff value of 3.775 g/L obtained by analyzing the receiver operating characteristic (ROC) curve of fibrinogen at diagnosis. Importantly, overall survival (OS) was markedly better in low fibrinogen group (p=.006) as well as disease-free survival (DFS) (p= ...
February 8, 2019: Leukemia & Lymphoma
Satoko Oka, Kazuo Ono, Masaharu Nohgawa
No abstract text is available yet for this article.
February 8, 2019: Leukemia & Lymphoma
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"